Valbenazine 40 mg, 60 mg, 80 mg Suppliers & Bulk Manufacturers

Available Forms: Capsules

Available Strengths: 40 mg, 60 mg, 80 mg

Reference Brands: Ingrezza (USA), Dysval

Category: Neurology

Valbenazine is a selective vesicular monoamine transporter-2 (VMAT2) inhibitor that decreases excessive dopamine release in nerve endings, helping control involuntary movements. It is approved for treating tardive dyskinesia in adults and chorea associated with Huntington’s disease. The drug is taken once daily, either as a whole capsule or as a sprinkle formulation over soft food. Common side effects include drowsiness, dizziness, and dry mouth, and it may cause QT prolongation, so heart monitoring is needed. It is metabolized in the liver, so dose adjustments may be required in hepatic impairment.

Product Description:

Valbenazine is a medication developed specifically for the treatment of tardive dyskinesia (TD), a neurological movement disorder that can occur after long-term use of certain antipsychotic or dopamine-blocking medicines. Approved by the U.S. Food and Drug Administration in 2017, it became the first therapy specifically indicated for adults with this condition. Valbenazine is marketed under the brand name Ingrezza and was developed by Neurocrine Biosciences.

Before the availability of valbenazine, treatment options for tardive dyskinesia were limited and often involved off-label use of medications or supplements such as tetrabenazine, clonazepam, or herbal products. Valbenazine works through a targeted mechanism involving inhibition of vesicular monoamine transporter 2 (VMAT2), which helps regulate dopamine release in the brain. By reducing excessive dopamine signaling associated with involuntary movements, the medicine helps improve TD symptoms.

Valbenazine is derived from tetrabenazine and is considered a purified prodrug of its most selective VMAT2-inhibiting component. This selective activity was designed to provide therapeutic benefits while improving tolerability. Clinical studies have shown that valbenazine can significantly reduce abnormal involuntary movements and provide a well-studied, evidence-based treatment option for adults living with tardive dyskinesia.